Abstract Rationale: Host genotypes can predict subtherapeutic anti-tubercular drug exposures and treatment-associated toxicities. Screening for these variants could enable personalized dosing, but scalable assays for second-line drugs are lacking. Objectives: We developed a nanopore sequencing panel to detect host variants affecting anti-tuberculosis drug troughs and toxicities, and evaluated its performance as a saliva-based screening tool.
Nanopore sequencing panel for saliva-based host pharmacogenomic screening in anti-tubercular therapy
calendar_today
September 4, 2026
person
Yadav, P., Shah, S. A. V., Babu, A. S., Paradkar, M., Vasanthaiah, S., Vasudevan, K., Arora, P. R., Lokhande, R. V., Pandya, H. U. B., Denti, P., Rodrigues, C., Andrews, J. R., Pandey, A., Tornheim, J. A., Ashavaid, T. F., Verma, R.
domain
medrxiv